SHAREHOLDER ALERT: WeissLaw LLP Reminds WMGI Shareholders of Its Ongoing Investigation

Author's Avatar
Jan 31, 2020
Article's Main Image

NEW YORK, Jan. 31, 2020 (GLOBE NEWSWIRE) -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Wright Medical Group N.V. (“WMGI” or the “Company”) ( WMGI) in connection with the proposed acquisition of the Company by Stryker Corporation (“SYK”) (: SYK). Under the terms of the acquisition agreement, SKY will acquire all outstanding WMGI shares for $30.75 in cash.

If you own WMGI shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website:

http://www.weisslawllp.com/wright-medical-group-nv/

Or please contact:
Joshua Rubin, Esq.
WeissLaw LLP
1500 Broadway, 16th Floor
New York, NY 10036
(212) 682-3025
(888) 593-4771
[email protected]

WeissLaw is investigating whether WMGI’s Board acted to maximize shareholder value prior to entering into the acquisition agreement. Notably, prior to the acquisition announcement, WMGI shares traded for $32.83, or approximately $2.00 above the per-share offer price. Furthermore, WMGI shares have performed strongly in the past year, up 13.61% in the last six months alone, with a 52-week high of $32.86.

Given these facts, WeissLaw is concerned whether the proposed acquisition undervalues the Company, and whether all material information related to the proposed acquisition is fully and fairly disclosed.

WeissLaw LLP has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties. We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases. If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at [email protected].

ti?nf=NzgwODUwNiMzMzEyMDQ5IzIwMTgyNTE=